D
DiaMonTech
Blood sugar testing device
About DiaMonTech
DiaMonTech GmbH is a pioneering medical technology company based in Berlin, Germany, specializing in non-invasive blood glucose monitoring. The company has developed a breakthrough product, the DMT Base, which uses laser-based technology to measure blood glucose levels without the need for painful finger pricks. This innovative approach aims to significantly improve the quality of life for diabetes patients by providing a pain-free and convenient method for glucose monitoring.
Read full description
DiaMonTech primarily serves diabetes patients in Germany, working closely with local pharmacies to distribute its products. The company operates in the healthcare and medical technology market, focusing on innovative solutions that address chronic health conditions. Its business model revolves around the development, certification, and distribution of medical devices, with revenue generated through product sales and partnerships with healthcare providers.
The company recently secured more than 7 million euros in a Series A financing round, led by Bioventure, a biotech and life science investor. This funding will support further development and commercialization of its technology. DiaMonTech's CE certification for the DMT Base confirms that its technology meets high safety and performance standards, positioning the company as a leader in non-invasive glucose monitoring.
At a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Berlin, Germany
- Employees
- 38
- Open positions
- None listed
- Dealroom signal
- 85.3/100
- Industry
- Health, Sports
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Diabetes, Testing, Sustainable Development Goals, EIT Health, Drug Delivery Systems, EIT Ecosystem, Horizon Europe, medical testing
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning DiaMonTech.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2025 | $8.8M | $89M | Companisto · Samsung Next | ↗ |
| SUPPORT PROGRAM✓Other financing | Jan 2025 | $0 | — | EIT Health | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for DiaMonTech is 7.3K monthly website visits, up 135.5% over the last three months. DiaMonTech's team grew 15.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Media Ventures
Macnica Ventures
Series A24 investors entered at this stage
IBB Ventures
Yuansheng BioVenture
Samsung Ventures
Unorthodox ventures
Moll family office- CGCelar GmbH
- MVMARSCH Ventures
- THTunica Holding
- TVTJK Ventures
- MIMORE Invest
- DIDS Invest
Golden Light- GSGlobal Agri Solutions
- GBGH BETEILIGUNGS-HOLDING
- YVYounity Ventures
- CGCovidien Group
The Kitchen- JVJSI Ventures
- RVRMG Ventures
- PGPangong GmbH
- DIDigiVen
Disrupt Technology Venture
Companisto
Samsung Next
Other known investors4 additional known investors
EIT Health
MedTech Innovator
German Accelerator
Suriyaa Sundararuban
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about DiaMonTech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See DiaMonTech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.